Dianthus Therapeutics Announces Proposed $400 Million Underwritten Public Offering (Upsized from Initial Plans)

on

Dianthus Therapeutics, Inc. (Nasdaq:
DNTH), a clinical-stage biotech company focused on severe autoimmune diseases, announced on March 9, 2026, a proposed $400 million underwritten public offering of common stock or pre-funded warrants.13

Underwriters have a 30-day option to purchase up to an additional $60 million in shares.13

Net proceeds will fund clinical and preclinical development, commercial readiness, working capital, and general corporate purposes.13

Joint book-running managers:
Jefferies, TD Cowen, Evercore ISI, Stifel, Guggenheim Securities, William Blair; LifeSci Capital as financial advisor.13

Offering is subject to market conditions; shelf registration effective January 30, 2026.13

User query references an upsized $625 million pricing, but search results confirm only the March 9 proposed $400 million offering announcement with no pricing details available yet.123

Sources:

1. https://www.biospace.com/press-releases/dianthus-therapeutics-inc-announces-proposed-400-million-underwritten-public-offering

2. https://www.streetinsider.com/Equity+Offerings/Dianthus+Therapeutics+announces+$400+million+public+stock+offering/26131874.html

3. https://www.stocktitan.net/news/DNTH/dianthus-therapeutics-inc-announces-proposed-400-million-puq6mv3lcf8f.html